WO2003103709A3 - Cd200-receptor mediated modulation of bone development - Google Patents

Cd200-receptor mediated modulation of bone development Download PDF

Info

Publication number
WO2003103709A3
WO2003103709A3 PCT/CA2003/000823 CA0300823W WO03103709A3 WO 2003103709 A3 WO2003103709 A3 WO 2003103709A3 CA 0300823 W CA0300823 W CA 0300823W WO 03103709 A3 WO03103709 A3 WO 03103709A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor mediated
bone development
mediated modulation
modulation
development
Prior art date
Application number
PCT/CA2003/000823
Other languages
French (fr)
Other versions
WO2003103709A2 (en
Inventor
Reginald M Gorczynski
Original Assignee
Trillium Therapeutics Inc
Reginald M Gorczynski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trillium Therapeutics Inc, Reginald M Gorczynski filed Critical Trillium Therapeutics Inc
Priority to CA002487428A priority Critical patent/CA2487428A1/en
Priority to JP2004510828A priority patent/JP4763282B2/en
Priority to US10/515,332 priority patent/US20050287603A1/en
Priority to EP03727091A priority patent/EP1532176A2/en
Priority to AU2003233721A priority patent/AU2003233721B2/en
Publication of WO2003103709A2 publication Critical patent/WO2003103709A2/en
Publication of WO2003103709A3 publication Critical patent/WO2003103709A3/en
Priority to US12/394,621 priority patent/US20090214573A1/en
Priority to AU2009217461A priority patent/AU2009217461A1/en
Priority to US13/084,009 priority patent/US20110189201A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Methods and compositions for modulating bone development are described.
PCT/CA2003/000823 2002-06-07 2003-06-06 Modulation of bone development WO2003103709A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002487428A CA2487428A1 (en) 2002-06-07 2003-06-06 Cd200-receptor mediated modulation of bone development
JP2004510828A JP4763282B2 (en) 2002-06-07 2003-06-06 How to control bone development
US10/515,332 US20050287603A1 (en) 2002-06-07 2003-06-06 Modulation of bone development
EP03727091A EP1532176A2 (en) 2002-06-07 2003-06-06 Cd200-receptor mediated modulation of bone development
AU2003233721A AU2003233721B2 (en) 2002-06-07 2003-06-06 CD200-receptor mediated modulation of bone development
US12/394,621 US20090214573A1 (en) 2002-06-07 2009-02-27 Modulation of bne development
AU2009217461A AU2009217461A1 (en) 2002-06-07 2009-09-23 CD200-receptor mediated modulation of bone development
US13/084,009 US20110189201A1 (en) 2002-06-07 2011-04-11 Modulation of bone development

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38656402P 2002-06-07 2002-06-07
US60/386,564 2002-06-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/394,621 Continuation US20090214573A1 (en) 2002-06-07 2009-02-27 Modulation of bne development

Publications (2)

Publication Number Publication Date
WO2003103709A2 WO2003103709A2 (en) 2003-12-18
WO2003103709A3 true WO2003103709A3 (en) 2004-04-08

Family

ID=29736181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2003/000823 WO2003103709A2 (en) 2002-06-07 2003-06-06 Modulation of bone development

Country Status (6)

Country Link
US (3) US20050287603A1 (en)
EP (1) EP1532176A2 (en)
JP (3) JP4763282B2 (en)
AU (2) AU2003233721B2 (en)
CA (1) CA2487428A1 (en)
WO (1) WO2003103709A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04003291A (en) * 2001-10-12 2004-07-23 Schering Corp Use of bispecific antibodies to regulate immune responses.
MXPA05006978A (en) * 2002-12-27 2005-08-16 Schering Corp Methods of inducing and maintaining immune tolerance.
CN101687033A (en) * 2007-01-11 2010-03-31 贝林格尔.英格海姆国际有限公司 Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
US8647871B2 (en) 2007-03-30 2014-02-11 Escape Therapeutics, Inc. Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells
WO2014113704A2 (en) 2013-01-18 2014-07-24 Escape Therapeutics, Inc. Enhanced differentiation of mesenchymal stem cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017543A2 (en) * 1999-09-03 2001-03-15 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2002020718A2 (en) * 2000-09-05 2002-03-14 The Rockefeller University Osteoclast-associated receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641747A (en) * 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
ES2330211T3 (en) * 2002-03-15 2009-12-07 Schering Corporation METHOD TO MODULATE CD200 RECEIVERS.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001017543A2 (en) * 1999-09-03 2001-03-15 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
WO2002020718A2 (en) * 2000-09-05 2002-03-14 The Rockefeller University Osteoclast-associated receptor

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GORCZYNSKI R M: "Transplant tolerance modifying antibody to CD200 receptor, but not CD200, alters cytokine production profile from stimulated macrophages", EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 31, August 2001 (2001-08-01), pages 2331 - 2337, XP002965417, ISSN: 0014-2980 *
GORCZYNSKI REGINALD M ET AL: "CD200 immunoadhesin suppresses collagen-induced arthritis in mice", CLINICAL IMMUNOLOGY (ORLANDO), vol. 101, no. 3, December 2001 (2001-12-01), pages 328 - 334, XP002264320, ISSN: 1521-6616 *
GORCZYNSKI REGINALD M ET AL: "CD200Fc and anti-CD200R regulates collagen induced arthritis (CIA) in mice", FASEB JOURNAL, vol. 16, no. 5, 22 March 2002 (2002-03-22), Annual Meeting of Professional Research Scientists on Experimental Biology;New Orleans, Louisiana, USA; April 20-24, 2002, pages A1045, XP009022374, ISSN: 0892-6638 *
HOEK-RM ET AL.: "Down-regulation of the macrophage lineage through interaction with OX2 (CD200)", SCIENCE, vol. 290, no. 5497, 1 December 2000 (2000-12-01), pages 1768 - 1771, XP002263649 *
KONG Y Y ET AL: "Molecular control of bone remodeling and osteoporosis", EXPERIMENTAL GERONTOLOGY, ELSEVIER SCIENCE, OXFORD, GB, vol. 35, no. 8, October 2000 (2000-10-01), pages 947 - 956, XP002233423, ISSN: 0531-5565 *
See also references of EP1532176A2 *
THEILL LARS E ET AL: "RANK-L and RANK: T cells, bone loss, and mammalian evolution.", ANNUAL REVIEW OF IMMUNOLOGY. UNITED STATES 2002, vol. 20, 2002, pages 795 - 823, XP001156511, ISSN: 0732-0582 *

Also Published As

Publication number Publication date
AU2003233721A1 (en) 2003-12-22
WO2003103709A2 (en) 2003-12-18
US20110189201A1 (en) 2011-08-04
US20050287603A1 (en) 2005-12-29
JP4763282B2 (en) 2011-08-31
AU2003233721B2 (en) 2009-07-02
CA2487428A1 (en) 2003-12-18
US20090214573A1 (en) 2009-08-27
JP2006501167A (en) 2006-01-12
JP2010285448A (en) 2010-12-24
AU2009217461A1 (en) 2009-10-15
EP1532176A2 (en) 2005-05-25
JP2010155843A (en) 2010-07-15

Similar Documents

Publication Publication Date Title
EA200500206A1 (en) METHOD AND COMPOSITIONS FOR MODULATION OF DEVELOPMENT AND FUNCTIONS OF T-HELPER CELLS (TX)
GB2423935B (en) Bone plates
SG148864A1 (en) Methods of treating cancer and related methods
EP1677735A4 (en) Methods and compositions for modulating adipocyte function
AP2001002225A0 (en) 1-heterocycle substituted diarylamines.
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
EP1583603A4 (en) Water-soluble products and methods of making and using the same
AU2002315407A1 (en) Compositions and methods for modulating plant development
ZA200410011B (en) Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment
WO2003059296A3 (en) Compositions comprising collagen and metalloprotease inhibitors
WO2004047749A3 (en) Purinergic modulation of smell
WO2003103571A3 (en) Flavivirus vaccines
AU4966101A (en) Methods of making and using 7alpha,11beta-dimethyl-17beta-hydroxy-4-estren-3-one17beta-trans-4-m-butylcyclohexane carboxylate and 7alpha,11beta-dimethyl-17beta -hydroxyestr-4-en-3-one 17-undecanoate
AU2003219788A1 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1Alpha-
SG148182A1 (en) Antiloading compositions and methods of selecting same
EP1509250A4 (en) Methods compositions and articles of manufacture for modulating bone growth
MX2007002277A (en) Methods for making retinoids and uses thereof.
AU2002362002A1 (en) Method and apparatus for an audio bridge
ATE433458T1 (en) SHIP-1 MODULATORS
WO2003103709A3 (en) Cd200-receptor mediated modulation of bone development
DE60316128D1 (en) N-sulfonylurea APOPTOSIS PROMOTERS
AU2002254132A1 (en) Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
WO2005055942A3 (en) Modulation of brain pathways and function
AU2002308665A1 (en) Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
AU2002256512A1 (en) Methods and compositions for modulating telomerase reverse transcriptase (tert) expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2487428

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004510828

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003233721

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003727091

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003727091

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10515332

Country of ref document: US